Marina Garassino, MD, University of Chicago, Chicago, IL, discusses the treatment of advanced non-small cell lung cancer (NSCLC) in 2021, highlighting regimens which combine chemotherapy and immunotherapy. Dr Garassino outlines key trials including the Phase III KEYNOTE-189 trial (NCT02578680) and the Phase III KEYNOTE-407 trial (NCT02775435) of chemotherapy with or without pembrolizumab in first-line metastatic non-squamous NSCLC, and the IMpower150 trial (NCT02366143) of atezolizumab plus carboplatin and paclitaxel with or without bevacizumab compared to carboplatin-paclitaxel-bevacizumab in stage IV non-squamous NSCLC. Finally, Dr Garassino gives an overview of the Phase III CheckMate 9LA trial (NCT03215706) investigating nivolumab plus ipilimumab with chemotherapy compared to chemotherapy alone in first-line treatment of NSCLC. This video was recorded at the virtual European Lung Cancer Congress (ELCC) 2021.